Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Predicting the future from the past: volatile markers for respiratory infections

Wojciech Filipiak, Clemens Ager, Jakob Troppmair
European Respiratory Journal 2017 49: 1700264; DOI: 10.1183/13993003.00264-2017
Wojciech Filipiak
1Breath Research Institute, University of Innsbruck, Dornbirn, Austria
2Dept of Pharmacodynamics and Molecular Pharmacology, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Torun, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clemens Ager
1Breath Research Institute, University of Innsbruck, Dornbirn, Austria
3Dept of Anesthesiology and Critical Care Medicine, Innsbruck Medical University, Innsbruck, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jakob Troppmair
4Daniel–Swarovski Research Laboratory, Dept of Visceral, Transplant and Thoracic Surgery, Innsbruck Medical University, Innsbruck, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jakob.troppmair@i-med.ac.at
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Volatile organic compounds (VOCs) for the detection of respiratory infections http://ow.ly/rdhy30aEGQt

To the Editor:

We read with great interest the editorial by Agusti [1] which reflected on past advances in technology in general, in respiratory medicine more specifically, and which tried to predict potential future advances. Among the latter, the use of exhaled biomarkers for detection of lung cancer caught our attention and we want to bring the editor's and readers’ attention to a rapidly advancing related field of respiratory medicine, namely the analysis of volatile biomarkers of bacterial infections in exhaled breath. Like all living cells, bacteria produce numerous volatile organic compounds (VOCs), of which some may be species-specific and thus provide a biological fingerprint of pathogen presence. Detection of such bacteria-derived metabolites in exhaled breath is completely non-invasive and can be performed repeatedly without any burden to the patient. It is increasingly recognised as an innovative and promising diagnostic technique for early detection of emerging pulmonary infections [2]. Furthermore, breath analysis has high potential to advance precision diagnosis of pathogens as it reflects individual susceptibility to disease causing agents and also to therapeutic agents. Apart from this, the potential for non-invasive “real-time” analysis of exhaled biomarkers and the application of portable, point-of-care, sensor-based devices for personalised monitoring of disease state and therapy progress is a clear advancement beyond the current state-of-the-art in clinical practice. Ultimately such methodology could lead to more timely and hence more effective antibiotic use.

Clinical implementation as a standardised diagnostic tool will, however, require further research. To this end, numerous in vitro experiments have been carried out to identify pathogen-specific VOCs and to investigate factors influencing their production (including culture media and environmental conditions, initial bacterial load and growth phase, inter-strain variation, fungal–bacterial interactions and drug susceptibility). Species-specific VOCs were found and the kinetics of their production found to be related to pathogen load [3]. Recent studies have extended knowledge on underlying metabolic pathways and the differentiation between pathogen-derived metabolites and VOCs originating from the human microbiome, or host immune and non-immune cells. Bean et al. [4] recently used a mouse model to correlate breath VOCs with the host's immune response and demonstrated that bacteria-induced changes in VOC levels are selective predictors for acute lung infections with Staphylococcus aureus and Pseudomonas aeruginosa. Similarly, Kleber et al. [5] linked alterations in exhalation profiles for 3-pentanone, in the course of lipopolysaccharide (LPS)- and tumour necrosis factor (TNF)-induced inflammation in ventilated rats, to the metabolism of branched-chain keto acids governed by dynamically changing demand for substrates for cellular energy.

To further advance the establishment of a genotype–phenotype relationship for VOC production by pathogens, Bos et al. [6] demonstrated the ability of bacteria to produce acetaldehyde, ethanol and methanol by linking the results of metagenomic sequencing of bacterial DNA fragments in the sputum of cystic fibrosis (CF) patients with the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. By combining these findings with the breath profiles of the CF patients who donated the sputum samples, the potential of breath-derived VOCs to predict respiratory tract colonisation/infection was illustrated. To further evaluate the metabolic activity of genetically encoded pathways of VOC production, Phan et al. [7] added stable, isotope-labelled substrates (13C6-D-glucose and 2H2O) to cultures of Pseudomonas aeruginosa, Rothia mucilaginosa and Streptococcus salivarius. Analysis of the 13C-labelled products revealed that acetaldehyde and ethanol, for example, were not produced through the glycolytic pathway but instead through a process involving the hydrolysis of 2H2O. Further stable-isotope labelling experiments would help to confirm the microbial origin of a particular metabolite and may play a role in future investigation of the metabolic interactions occurring during polymicrobial infection.

Translation of this approach into the clinical setting was recently achieved by us in a prospective pilot clinical study where volatile metabolites produced by Staphylococcus aureus and Candida albicans under in vitro conditions were monitored in the breath of mechanically-ventilated patients. In persons infected with these microbes, the concentration profiles of exhaled VOCs corresponded to the severity of ventilation-associated pneumonia (VAP) [8]. This approach also appeared to work in patients where conventional cultivation of microorganisms from isolates failed, but where a change in the exhaled concentration profile of species-specific volatiles (e.g. 1-undecene) still hinted at the presence of a pathogen (most likely Pseudomonas aeruginosa) based on previously established in vitro profiles [8].

Considering the frequent lack of reproducibility associated with many findings [9], multicentre studies focused on promising biomarker candidates are an urgent next step. Here, key parameters of a future breath test (e.g. sensitivity and specificity) should be evaluated on independent cohorts of patients and healthy controls. Advancement in analytical techniques, especially in small and VOC-selective sensor arrays, should enable larger studies, improving their statistical power. Cheap, miniaturised “eNose” sensors have already been used in pilot clinical studies inter alia, to identify bacterial colonisation in clinically stable patients with chronic obstructive pulmonary disease [10], and they will ultimately lead to the personalised monitoring of disease state and therapy control.

Footnotes

  • Conflict of interest: None declared.

  • Received February 6, 2017.
  • Accepted February 20, 2017.
  • Copyright ©ERS 2017

References

  1. ↵
    1. Agustí A
    . Predicting the future from the past. Eur Respir J 2017; 49: 1601854.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Macht M,
    2. Robinson JC,
    3. Graham BB
    . Updated approach for the assessment of ventilator-associated pneumonia. Crit Care Med 2013; 41: 2641–2642.
    OpenUrl
  3. ↵
    1. Filipiak W,
    2. Sponring A,
    3. Baur MM, et al.
    Molecular analysis of volatile metabolites released specifically by Staphylococcus aureus and Pseudomonas aeruginosa. BMC Microbiol 2012; 12: 113.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Bean HD,
    2. Jiménez-Díaz J,
    3. Zhu J, et al.
    Breathprints of model murine bacterial lung infections are linked with immune response. Eur Respir J 2015; 45: 181–190.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Kleber A,
    2. Maurer F,
    3. Lorenz D, et al.
    Metabolism of 3-pentanone under inflammatory conditions. J Breath Res 2016; 10: 047101.
    OpenUrl
  6. ↵
    1. Bos LD,
    2. Meinardi S,
    3. Blake D, et al.
    Bacteria in the airways of patients with cystic fibrosis are genetically capable of producing VOCs in breath. J Breath Res 2016; 10: 047103.
    OpenUrl
  7. ↵
    1. Phan J,
    2. Meinardi S,
    3. Barletta B, et al.
    Stable isotope profiles reveal active production of VOCs from human-associated microbes. J Breath Res 2017; 11: 017101.
    OpenUrl
  8. ↵
    1. Filipiak W,
    2. Beer R,
    3. Sponring A, et al.
    Breath analysis for in vivo detection of pathogens related to ventilator-associated pneumonia in intensive care patients: a prospective pilot study. J Breath Res 2015; 9: 016004.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Baker M
    . Is there a reproducibility crisis? Nature 2016; 533: 452–454.
    OpenUrlCrossRef
  10. ↵
    1. Sibila O,
    2. Garcia-Bellmunt L,
    3. Giner J, et al.
    Identification of airway bacterial colonization by an electronic nose in chronic obstructive pulmonary disease. Respir Med 2014; 108: 1608–1614.
    OpenUrl
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 49 Issue 5 Table of Contents
European Respiratory Journal: 49 (5)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Predicting the future from the past: volatile markers for respiratory infections
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Predicting the future from the past: volatile markers for respiratory infections
Wojciech Filipiak, Clemens Ager, Jakob Troppmair
European Respiratory Journal May 2017, 49 (5) 1700264; DOI: 10.1183/13993003.00264-2017

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Predicting the future from the past: volatile markers for respiratory infections
Wojciech Filipiak, Clemens Ager, Jakob Troppmair
European Respiratory Journal May 2017, 49 (5) 1700264; DOI: 10.1183/13993003.00264-2017
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Info & Metrics
  • PDF

Subjects

  • Respiratory clinical practice
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • D-dimer cut-offs and machine learning for ruling out pulmonary embolism
  • Sputum cell counts in COPD patients who use electronic cigarettes
  • Extracorporeal life support allows lung transplant in rapidly progressive ILD
Show more Agora

Correspondence

  • Extracorporeal life support as a bridge to lung transplantation strategy in anti-MDA5+ rapidly progressive interstitial lung disease is life-saving but with persistent difficulties at the bedside
  • Liver cancer in severe alpha-1 antitrypsin deficiency: Who is at risk?
  • Cancer risk in severe alpha-1-antitrypsin deficiency - the importance of the early identification
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society